Tao Wang, Yaojun Wang, Yue Zhang, Jiaoni Chi, Qiang Li
{"title":"中国COVID-19疫苗接种后白癜风加重的回顾性统计分析","authors":"Tao Wang, Yaojun Wang, Yue Zhang, Jiaoni Chi, Qiang Li","doi":"10.1155/2023/4711236","DOIUrl":null,"url":null,"abstract":"At present, COVID-19 vaccination is an effective method to stop the spread of the epidemic and reduce disease severity and mortality. It has been reported that COVID-19 vaccine can activate several autoimmune diseases. However, whether it can affect development of vitiligo remains elusive. In this study, we aimed to evaluate the possible risk factors of vitiligo disease activity or recurrence after COVID-19 vaccination. We recruited 383 vitiligo patients, of whom 126 were not vaccinated and 257 had received the COVID-19 vaccine. Vitiligo disease activity (VIDA) score was used to analyze key risk factors of vitiligo in patients who underwent COVID-19 vaccination. Multivariate logistic regression models were used to explore the risk factors associated with VIDA. Compared with patients without history of undergoing vaccination, the VIDA score of vaccinated patients increased significantly (3(2, 4) vs. 3(2, 3) scores, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>P</mi> <mtext> </mtext> <mo><</mo> <mtext> </mtext> <mn>0.01</mn> </math> ). Logistic regression analysis identified COVID-19 vaccination (odds ratio (OR): 3.040, 95% confidence interval (CI): 1.649–5.603) as an independent risk factor for VIDA. The data showed that COVID-19 vaccination aggravated the development of vitiligo, which is a key risk factor for recurrence.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"18 1","pages":"0"},"PeriodicalIF":3.7000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Retrospective Statistical Analysis of Vitiligo Exacerbation after COVID-19 Vaccination in China\",\"authors\":\"Tao Wang, Yaojun Wang, Yue Zhang, Jiaoni Chi, Qiang Li\",\"doi\":\"10.1155/2023/4711236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"At present, COVID-19 vaccination is an effective method to stop the spread of the epidemic and reduce disease severity and mortality. It has been reported that COVID-19 vaccine can activate several autoimmune diseases. However, whether it can affect development of vitiligo remains elusive. In this study, we aimed to evaluate the possible risk factors of vitiligo disease activity or recurrence after COVID-19 vaccination. We recruited 383 vitiligo patients, of whom 126 were not vaccinated and 257 had received the COVID-19 vaccine. Vitiligo disease activity (VIDA) score was used to analyze key risk factors of vitiligo in patients who underwent COVID-19 vaccination. Multivariate logistic regression models were used to explore the risk factors associated with VIDA. Compared with patients without history of undergoing vaccination, the VIDA score of vaccinated patients increased significantly (3(2, 4) vs. 3(2, 3) scores, <math xmlns=\\\"http://www.w3.org/1998/Math/MathML\\\" id=\\\"M1\\\"> <mi>P</mi> <mtext> </mtext> <mo><</mo> <mtext> </mtext> <mn>0.01</mn> </math> ). Logistic regression analysis identified COVID-19 vaccination (odds ratio (OR): 3.040, 95% confidence interval (CI): 1.649–5.603) as an independent risk factor for VIDA. The data showed that COVID-19 vaccination aggravated the development of vitiligo, which is a key risk factor for recurrence.\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"18 1\",\"pages\":\"0\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2023-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/4711236\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/4711236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
A Retrospective Statistical Analysis of Vitiligo Exacerbation after COVID-19 Vaccination in China
At present, COVID-19 vaccination is an effective method to stop the spread of the epidemic and reduce disease severity and mortality. It has been reported that COVID-19 vaccine can activate several autoimmune diseases. However, whether it can affect development of vitiligo remains elusive. In this study, we aimed to evaluate the possible risk factors of vitiligo disease activity or recurrence after COVID-19 vaccination. We recruited 383 vitiligo patients, of whom 126 were not vaccinated and 257 had received the COVID-19 vaccine. Vitiligo disease activity (VIDA) score was used to analyze key risk factors of vitiligo in patients who underwent COVID-19 vaccination. Multivariate logistic regression models were used to explore the risk factors associated with VIDA. Compared with patients without history of undergoing vaccination, the VIDA score of vaccinated patients increased significantly (3(2, 4) vs. 3(2, 3) scores, ). Logistic regression analysis identified COVID-19 vaccination (odds ratio (OR): 3.040, 95% confidence interval (CI): 1.649–5.603) as an independent risk factor for VIDA. The data showed that COVID-19 vaccination aggravated the development of vitiligo, which is a key risk factor for recurrence.
期刊介绍:
Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.